sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign doxazosin 2mg tablets hyperplasia.On doxazosin 2mg tablets 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor.

C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic doxazosin 2mg tablets cat. ?Legal status doxazosin 2mg tablets Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under doxazosin 2mg tablets brand names Cardura® and Carduran® , doxazosin 2mg tablets an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the doxazosin 2mg tablets FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used doxazosin 2mg tablets treat high blood pressure and benign prostatic hyperplasia.On doxazosin 2mg tablets doxazosin 2mg tablets 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker.

an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, doxazosin 2mg tablets US FDA.